Table 3 Cross-sectional associations of 3 myocardial stress markers with CKDcr-cys a.

From: Longitudinal and cross-sectional associations of myocardial stress markers with kidney function and chronic kidney disease in the BiomarCaRE project

Markers

Items

Categories of markersb

per 1 SD increase in log-transformed

G1

G2

G3

G4

NT-proBNP

Median, pg/ml

25.4

72.5

169.4

501.2

48.0

 

Cases/controls (%)

365/30,574 (1.2%)

530/20,754 (2.6%)

538/6571 (8.2%)

523/1975 (26.5%)

1956/59,874 (3.3%)

 

Model 1

Ref

1.35 (1.17, 1.55) ***

2.62 (2.25, 3.06) ***

6.14 (5.22, 7.24) ***

1.84 (1.75, 1.93) ***

 

Model 2

Ref

1.37 (1.19, 1.58) ***

2.56 (2.19, 2.99) ***

5.72 (4.82, 6.78) ***

1.81 (1.72, 1.90) ***

MR-proANP

Median, pmol/l

30.8

53.7

92.8

147.2

46.8

 

Cases/controls (%)

39/3501 (1.1%)

124/4369 (2.8%)

58/990 (5.9%)

79/339 (23.3%)

300/9199 (3.3%)

 

Model 1

Ref

1.48 (1.00, 2.21)

2.22 (1.40, 3.57) ***

7.35 (4.63, 11.8) ***

1.92 (1.70, 2.18) ***

 

Model 2

Ref

1.54 (1.05, 2.31) *

2.17 (1.36, 3.50) **

6.39 (3.96, 10.5) ***

1.80 (1.58, 2.05) ***

MR-proADM

Median, nmol/l

0.37

0.50

0.66

0.86

0.46

 

Cases/controls (%)

32/3460 (0.9%)

98/4299 (2.3%)

58/971 (6.0%)

108/301 (35.9%)

296/9031 (3.3%)

 

Model 1

Ref

1.86 (1.25, 2.84) **

4.52 (2.83, 7.35) ***

28.8 (18.1, 46.8) ***

2.93 (2.59, 3.32) ***

 

Model 2

Ref

2.02 (1.35, 3.12) ***

5.04 (3.08, 8.36) ***

34.6 (20.8, 58.6) ***

3.04 (2.65, 3.48) ***

  1. aLogistic regression was used to estimate OR and 95% CI of prevalent CKD for G2-4 compared with G1 of markers, as well as for per 1 SD increase in log-transformed markers. Only results for CKDcr-cys are presented in this table, while results for all three CKD assessments are presented in Table S7.
  2. bCategories of NT-proBNP: G1: < 48; G2: 48–125; G3: 125–300; G4: ≥ 300 pg/ml. Categories of MR-proANP: G1: < 40; G2: 40–80; G3: 80–120; G4: ≥ 120 pmol/l. Categories of MR-proADM: G1: < 0.425; G2: 0.425–0.609; G3: 0.609–0.766; G4: ≥ 0.766 nmol/l.
  3. Model 1: adjusted for age, sex, and study cohort;
  4. Model 2: model 1 plus body mass index, smoking status, alcohol consumption, systolic blood pressure, use of antihypertensive medication, high-density lipoprotein cholesterol, log-transformed triglycerides, diabetes, and cardiovascular diseases.
  5. CI, confidence interval; CKD, chronic kidney disease; CKDcr-cys, creatinine and cystatin C-based CKD; G, group; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OR, odds ratio; Ref, reference; SD, standard deviation.
  6. * p < 0.05, ** p < 0.01, *** p < 0.001.
Back to article page